Full Breakdown
Bacterial-Derived Peptide aurB Halts Tumor Growth by Disrupting Mitochondrial Energy Production
5/9/2026, 9:28:00 PM
Preclinical Success of aurB in Prostate Cancer Models
Researchers at the University of Illinois Chicago (UIC) found that the synthetic peptide aurB markedly reduced tumor growth in hormone-resistant prostate-cancer mouse models. Combined with radiation, aurB slowed tumor expansion without observable toxicity. The results appeared in *Signal Transduction and Targeted Therapy* on 7 April 2026.
Background: Tumor-Associated Bacteria and Prior Cupredoxin Work
Tumors host bacterial communities that influence the microenvironment. Earlier UIC work identified a bacterial cupredoxin that suppressed tumor growth but required functional p53, often mutated in cancers. The team therefore sought a bacterial protein that targets cellular energy production instead of p53 pathways.
Key Researchers and Institutional Partners
The study was led by senior author Tohru Yamada, associate professor of surgery and biomedical engineering at UIC and member of the University of Illinois Cancer Center. The research was supported by UIC’s Office of Technology Management, which filed a patent for aurB.
Mechanism of Action and Preclinical Data
DNA sequencing of breast-cancer patient samples identified a bacterial species producing the cupredoxin auracyanin. Using auracyanin as a template, the researchers engineered aurB, a peptide that penetrates tumor-cell mitochondria and binds ATP synthase, the enzyme that generates ATP. In p53-deficient cell lines and in the tibial bone-metastatic mouse model, aurB alone entered mitochondria, but its anti-tumor activity was amplified when combined with radiation, leading to significantly smaller tumors.
Potential Clinical Impact and Limitations
By targeting mitochondrial energy factories, aurB offers a p53-independent therapeutic avenue, potentially broadening applicability across cancers with diverse p53 mutations. However, efficacy has so far been demonstrated only in vitro and in murine models; human safety and effectiveness remain untested.
Official Statements & Institutional Responses
UIC officials emphasized that disrupting mitochondrial function addresses a fundamental requirement for rapid cancer cell proliferation. The university’s technology office highlighted the secured patent as a step toward translating the discovery into clinical applications.
Conflicting Reports & Gaps
The study reports “no clear signs of toxicity” in mice, but does not provide quantitative toxicity metrics or long-term safety data. Additionally, the therapeutic benefit has been shown only in prostate-cancer models; efficacy in other tumor types remains uncertain.
Verbatim Quotes
- “The mitochondria are very important for a cell to survive; they are the energy factories,” — Tohru Yamada, Associate Professor, UIC
- “Many cancer cells exhibit altered mitochondrial number and activity, because a cancer cell has to grow aggressively and rapidly. Therefore, the mitochondria would be an ideal target for cancer therapy.” — Tohru Yamada
- “The combination significantly enhanced the activity of the peptide and the tumor became much smaller,” — Tohru Yamada
- “There are many other bacterial proteins that could be source of cancer drugs,” — Tohru Yamada
Next Steps Toward Human Trials
The research team has filed a patent for aurB and is exploring regulatory pathways to initiate Phase I clinical trials. Ongoing work aims to identify additional bacterial proteins that could be adapted into similar mitochondria-targeting therapeutics.
